Clinical Trials Sponsored by Boston Pharmaceuticals

Total 23703 results

Boston Pharmaceuticals

Completed

Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care

Systemic Lupus Erythematosus

United States, Philippines, Hungary, Poland, Mexico, Colombia, Ukraine, Peru, Romania, Argentina, Bulgaria, Georgia
Boston Pharmaceuticals

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Diarrhea-predominant Irritable Bowel Syndrome

United States
Boston Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris

Moderate to Severe Acne Vulgaris

United States, Canada
Boston Pharmaceuticals

Completed

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects

Healthy Participants

United States
Boston Pharmaceuticals

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Topical Administration of BOS-475 in Healthy Subjects and Patients With Psoriasis

Psoriasis

Australia
Boston Pharmaceuticals

Completed

Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects

Healthy Subjects

United Kingdom
Boston Pharmaceuticals

Completed

Study to Determine the Relative Bioavailability, Single and Repeat Dose Pharmacokinetics, Safety and Tolerability of BOS172767 Enantiomers in Healthy Subjects

Healthy Participants

United Kingdom
Boston Pharmaceuticals

Recruiting

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States
Boston Pharmaceuticals

Completed

Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test

Chronic Plaque Psoriasis

Germany
Boston Pharmaceuticals

Completed

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

Advanced Nonhaematologic Malignancies

United States, Korea, Republic of, Taiwan, France, Hong Kong, Belgium, Spain
Boston Pharmaceuticals

Completed

Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies

Advanced Nonhaematologic Malignancies

United Kingdom
Boston University
Ligand Pharmaceuticals

Completed

Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma

Cutaneous T-Cell Lymphoma

United States
Boston University
Regeneron Pharmaceuticals

Completed

IL1-TRAP, Rilonacept, in Systemic Sclerosis

Systemic Sclerosis | Scleroderma | Diffuse Systemic Sclerosis | Diffuse Scleroderma

United States
Boston University
Aspreva Pharmaceuticals

Completed

Mycophenolate Mofetil in Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis

United States
Boston University
HemaQuest Pharmaceuticals Inc.

Completed

Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon (LB-04-THAL)

Beta Thalassemia Intermedia

Lebanon
HemaQuest Pharmaceuticals Inc.
Boston University

Terminated

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

EBV Lymphomas | Lympho-proliferative Diseases

United States
Boston Medical Center
Janssen Pharmaceuticals

Completed

Daratumumab for the Treatment of Patients With AL Amyloidosis

AL Amyloidosis

United States
Boston Children's Hospital
BioMarin Pharmaceutical

Completed

Nutrition Status of Adults With PKU Before and During Treatment With Pegvaliase

Phenylketonurias

United States
Boston Children's Hospital
BioMarin Pharmaceutical

Completed

Nutrition Status of Adults Treated With Pegvaliase

Phenylketonurias

United States
Boston Medical Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Amyloidosis

United States
Boston Children's Hospital
Agios Pharmaceuticals, Inc.

Completed

Pyruvate Kinase Deficiency Natural History Study (PKD NHS)

Pyruvate Kinase Deficiency | Congenital Non-Spherocytic Hemolytic Anemia

United States, Germany, Canada, Czechia, Italy, Netherlands
Boston Medical Center
Spectrum Pharmaceuticals, Inc

Terminated

Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients

Amyloidosis; Systemic

United States
Ophthalmic Consultants of Boston
Regeneron Pharmaceuticals

Completed

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion (ANDROID)

Central Retinal Vein Occlusion | Proliferative Diabetic Retinopathy

United States
Boston Scientific Corporation
Pharmaceutical Research Associates

Completed

TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System European Post-Approval Surveillance Study (TE-Prove) (TE-Prove)

Coronary Heart Disease

Spain, Belgium, Latvia, United Kingdom, Germany, France, Ireland, Italy, Poland, Hungary
Boston Medical Center
Cepheid; Optimer Pharmaceuticals LLC

Completed

Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients

Crohn's Disease | Ulcerative Colitis | Inflammatory Bowel Disease | Clostridium Difficile

United States
Boston University
Takeda Pharmaceuticals North America, Inc.

Completed

Use of Expressive Writing in Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome
Boston VA Research Institute, Inc.
Millennium Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
East Carolina University
Boston University; University of Houston

Completed

Evaluation of Web-Based CBT for Rape Victims

PTSD
Caleb Nelson
Otsuka America Pharmaceutical

Completed

TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study (TCUPS)

Cystinuria

United States
Boston Scientific Corporation
Pharmaceutical Research Associates; Medidata Solutions

Completed

PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study (PE-Prove)

Coronary Heart Disease

Spain, Ireland, Denmark, United Kingdom, Belgium, Germany, France, Netherlands, Italy, Austria, Hungary
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Boston Medical Center
Boston University

Completed

Evaluation of Medium Chain Triglycerides in a Mixed Racial Population of Patients: a Feasibility Study

Insulin Resistance

United States
Boston University
Boston Medical Center

Terminated

Transcranial Magnetic Stimulation in Major Depression With EEG and Near Infrared Spectroscopy (NIRS) Monitoring

Depression

United States
Jeffrey S Heier
Regeneron Pharmaceuticals

Unknown

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD (PRO-CON)

Age-Related Macular Degeneration

United States
Boston Medical Center
Boston University

Completed

Nefazodone in the Treatment of Cocaine Dependence and Depression - 4

Substance-Related Disorders | Cocaine-Related Disorders

United States
Boston Medical Center
Boston University

Completed

Weight Management Among Breast Cancer Survivors

Body Weight

United States
Boston Children's Hospital
Boston Public Schools

Completed

Youth Substance Use Prevention/Reduction Through Science-based Drug Abuse Education

Substance Abuse

United States
Greater Houston Retina Research
Regeneron Pharmaceuticals

Completed

Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial

Diabetic Macular Edema

United States
University of Houston
Paratek Pharmaceuticals Inc

Completed

Microbiome Effect of Omadacycline on Healthy Volunteers

Healthy Volunteers

United States
Boston Children's Hospital
Boston Orthotics & Prosthetics

Completed

Premie Pouch to Manage Deformational Plagiocephaly in Very Low Birth Weight Infants

Plagiocephaly

United States
Boston Children's Hospital
Boston Orthotics & Prosthetics

Terminated

Cranial Cup Use for the Prevention of Positional Head Shape Deformity in the NICU

Plagiocephaly | Brachycephaly | Scaphocephaly

United States
Boston College

Not yet recruiting

Causal Role of Brain Networks in Episodic Memory

Healthy | Episodic Memory
Boston University

Active, not recruiting

Genetics of Ehlers-Danlos Syndrome

Ehlers-Danlos Syndrome | Genetics Syndrome

United States
Boston Sight

Withdrawn

Novel Use of Restasis and PROSE Devices

Ocular Surface Disease

United States
Boston University

Completed

Solius UV Light Source in Improving Serum Levels of 25-hydroxyvitamin D

Vitamin D Deficiency | Vitamin D Insufficiency

United States
Boston IVF

Active, not recruiting

Impact of Endometrial Compaction in Euploid Frozen Embryo Transfers

Infertility, Female

United States
Boston University

Terminated

Effects of TUDCA on Endothelial Function in Type 2 DM

Diabetes Mellitus, Type 2 | Endothelial Dysfunction | Insulin Response

United States
Boston University

Terminated

Laser Enucleation of Prostate (LEP) Versus Transurethral Resection of Prostate (TURP)

Benign Prostatic Hyperplasia

United States

Clinical Trials Sponsored by Boston Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations